Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen | Zendy

Clotilde Allavena | Zendy; Kalyane BachNgohou | Zendy; Eric Billaud | Zendy; Solène Sécher | Zendy; Thomas Dejoie | Zendy; Véronique Reliquet | Zendy; Fádi Fakhouri | Zendy; François Raffi | Zendy

Open Access

Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen

Author(s) -

Clotilde Allavena,

Kalyane BachNgohou,

Eric Billaud,

Solène Sécher,

Thomas Dejoie,

Véronique Reliquet,

Fádi Fakhouri,

François Raffi

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt265

Subject(s) - abacavir , emtricitabine , lamivudine , medicine , nevirapine , urology , gastroenterology , nephrotoxicity , population , kidney disease , regimen , pharmacology , kidney , immunology , viral load , hepatitis b virus , human immunodeficiency virus (hiv) , antiretroviral therapy , virus , environmental health

Tenofovir may be associated with nephrotoxicity. Several studies have shown that an early increase in urinary neutrophil gelatinase-associated lipocalin (NGAL) may predict the occurrence of acute kidney injury. We investigated urine and plasma NGAL in patients on long-term treatment with nevirapine associated with either tenofovir/emtricitabine or abacavir/lamivudine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research